Knockdown of NSD1 in head and neck cancer cells resulted in decreased expression of CCL5 and suppressed T-cell infiltration into the tumor microenvironment, suggesting that NSD1 inactivation in cancer has implications for cancer immunotherapy [100]. This evidence concerns the gene CCL5 and cancer.